LB 2102
Alternative Names: LB-2102Latest Information Update: 17 Jun 2025
At a glance
- Originator Legend Biotech USA
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Neuroendocrine carcinoma; Small cell lung cancer
Most Recent Events
- 03 Jun 2025 Efficacy and adverse events data from a phase I trial in Small-cell lung cancer released by Legend Biotech
- 30 May 2025 Efficacy, pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Neuroendocrine carcinoma and Small cell lung cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 03 Jan 2024 Legend Biotech USA closes license agreement with Novartis Pharma AG